Fluorotronics, Inc & Co., USA
Dr. Farid Menaa is an inter- and multi-disciplinary professional. Professor, Director, Entrepreneur and Consultant, he was awarded with a National Master in Genetics in 1999 and PhD in Medicine (Geriatry/Gerontology, Biochemistry and Biophysics) in 2003, both with highest distinctions from prestigious French universities. Dr. Menaa followed a post-doctoral in Oncology as a NIH-fellow (San Diego, California, USA; 2004–2007), during which he discovered a novel radiation-induced DNA Damage Signaling Pathway. Subsequently, Dr. Menaa pursed his career in Dermatology and Stem Cells as a DFG-Fellow (Wuerzburg, Germany; 2007–2009), during which he pointed out the clinical relevance of skin cancer stem cells for prognosis, diagnosis and therapy. Dr. Menaa was promoted as Chief Scientific Officer and Vice-President R&D at Fluorotronics, Inc. (CA, USA; 2009–1010), during which he actively participated in the development of Carbon-Fluorine Spectroscopy (CFS, aka Spectro-Fluor™) for bio-medical and pharmaceutical applications. Further, Dr. Menaa was appointed Principal Investigator in Hematology and Genomics as a FAPESP-Fellow (São Paulo, Brazil; 2010–2012) during which he discovered new genetic variants of stroke in sickle cell anemia patients. Dr. Menaa followed various formations (Medecine, Pharmacy, Chemistry, Nanotechnology, Bioinformatics, Executive MBA in Entrepreneurship...). His main current focuses are related to personalized, translational and integrative medicine. Dr. Menaa has a strong experience with teaching, consulting, research, collaborations in several countries. Dr. Menaa is a member of several prestigious organizations (medical and scientific societies), editor and reviewer of a number of esteemed journals worldwide. Dr. Menaa authored and co-authored more than 100 publications, including in biophysics (including research and review articles, books and book chapters, proceedings, patents). Dr. Menaa is often invited as a speaker and chairman to reputed world congresses and institutions, and is offering speeches in various areas of medicine, sciences and technology.
Nanomaterials (e.g. nanoparticles), nanoscale biodevices (e.g. biosensors, arrays) and genomic platforms along human sequencing projects (e.g. GWAS) are revolutionizing medicine. The recent advancements of the nanobiotechnology and genomics are quite promising. They can be combined or not, but both are contributing to prevention, diagnosis, prognosis and therapy of patients in a faster, personalized and hopefully in a safer and cost-effective manner. Since the past decade, tremendous advancement has been made toward developing nanoscale biosensors (e.g. graphenebased), drug and nutraceutical delivery nanosystems (e.g. fluorinated nanoparticles) which are valuable for diagnosis and/or therapy (i.e. nanotheranostics). Biocompatible and biodegradable nanocarriers are usually of 1-100 nm in size, loaded with a substance are intended to improve the diagnosis (e.g. nano-imaging) and/or the therapeutic index (e.g. bioavailability, stability). Also, several methods of nanoencapsulation (e.g. nanoprecipitation) and nanodevices (e.g. biosensors) have been employed for drug delivery, targeting and/or imaging, tissue engineering and regenerative medicine. Besides, the current revolution in genomics (i.e. the science of monitoring genes, epigenes, and gene products using high throughput approaches) allows the determination of our entire DNA sequence (e.g. by NGS, arrays) but also understand how our specific genome sequence can inform our health (e.g. signaling pathways, mutations, polymorphisms). Such sequence and molecular omics profiling (e.g. proteomics, glucomics, lipidomics) is expected to be powerful in preventing, detecting, understanding, and treating complex diseases such as cancer and inherited diseases that are otherwise difficult to diagnose. My keynote speech will be all about facts and artifacts, ties and lies, trends and prospects, hopes and insights for the Environment and Humanity!